Posted: March 14, 2008

Arrowhead CEO Presents 2008 Objectives

(Nanowerk News) Arrowhead Research Corporation’s (NASDAQ:ARWR) Chief Executive Officer, Christopher Anzalone, presented a slide show entitled “Creating Value by Building Nanobusiness from Nanoscience” following Arrowhead’s Annual Meeting of Stockholders. Dr. Anzalone began by describing the market opportunity presented by advances in nanoscience and Arrowhead’s key value drivers. He described the advantages of Arrowhead’s business model and his vision of the company as an institutional entrepreneur.
Dr. Anzalone briefly described each of Arrowhead’s subsidiaries, their opportunities and progress to date, as well as adjustments that are being made to streamline and make improvements at both the Arrowhead level and in the subsidiaries. Operational targets for 2008 were outlined for each of Arrowhead’s subsidiary companies, including investigator-led Phase II trials for Insert’s drug candidate, IT-101, an industry partnership for Calando’s siRNA delivery system, and various industry partnerships and outlicenses for Unidym.
Dr. Anzalone concluded the presentation by introducing Nanotope and Leonardo Biosystems, both portfolio companies co-founded by Dr. Anzalone and co-owned in part by The Benet Group, LLC. The Benet Group is owned by Dr. Anzalone, and the company expects to submit acquisition of The Benet Group for approval by Arrowhead stockholders in Spring 2008.
Dr. Mauro Ferrari, Director of Scientific Strategy of Arrowhead and co-founder of Leonardo Biosystems, a development stage drug delivery company, explained how the company is developing an advanced set of nanotechnology tools to deliver cancer therapeutics. Dr. Anzalone described Nanotope, a development stage regenerative medicine company that seeks to provide customized products to advance regeneration of specific tissues, including neuronal, vascular, bone, myocardial, and cartilage.
Dr. Anzalone’s presentation, followed by a question and answer period, was broadcast live via the Internet and by teleconference. A replay will be available for 90 days for those who were unable to attend the live broadcast. Information on how to access the webcast can be accessed on Arrowhead’s website at
About Arrowhead Research Corporation
Arrowhead Research Corporation ( is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has five subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, fullerene anti-oxidants, carbon-based electronics and compound semiconductor materials.
Source: Arrowhead Research Corporation
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: